Bicara Therapeutics Inc
BCAXHealthcare|Biotechnology|USA
$28.88
-0.77 (-2.59%)
Tangible Book
$7.84
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06788990 FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | P2P3 | Recruiting | 650 | RCT, Double-blind | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo |
| NCT07465276 Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC | Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck | P2 | Recruiting | 32 | Open-label | Ficerafusp alfa, Pembrolizumab |
| NCT04429542 Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal | P1 | Recruiting | 292 | Open-label | BCA101, Pembrolizumab |
| NCT07552558 Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | P1P2 | Not Yet Recruiting | 45 | Open-label | Pembrolizumab, Ficerafusp alfa |
| NCT07529873 Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck (SCCHN) | P2 | Not Yet Recruiting | 131 | RCT, Open-label | Ficerafusp alfa, Nivolumab |